Skip to main content

Table 1 Characteristics of subjects with ESCC

From: The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy

Gender Male 61 (83.6%)
Female 12 (16.4%)
Age Mean ± SD, (y) 69.0 ± 8.2
Weight Mean ± SD, (kg) 53.9 ± 8.8
Height Mean ± SD, (cm) 161.1 ± 8.0
Performance status 0 18 (24.7%)
1 39 (53.4%)
2 16 (21.9%)
3 0 (0.0%)
eGFR Mean ± SD, (ml/min/1.73 m2) 78.0 ± 20.5
Tumor location (primary site) Ce 9 (12.3%)
Ut 11 (15.1%)
Mt 35 (47.9%)
Lt 18 (24.7%)
EGJ 0 (0.0%)
Number of pre-CRT biopsy samples Median with range, (n) 2 (1–6)
Histological type Well differentiated SCC 10 (13.7%)
Moderately differentiated SCC 54 (74.0%)
Poorly differentiated SCC 9 (12.3%)
Basaloid SCC 0 (0.0%)
Depth of invasion cTis 0 (0.0%)
cT1a 0 (0.0%)
cT1b 15 (20.5%)
cT2 9 (12.3%)
cT3 22 (30.1%)
cT4a 12 (16.4%)
cT4b 15 (20.5%)
Tumor size Median with range, (cm) 5.0 (1.0–10.5)
Lymph node metastasis cN0 24 (32.9%)
cN1 12 (16.4%)
cN2 32 (43.8%)
cN3 5 (6.8%)
Distant metastasis cM0 63 (86.3%)
cM1-lym 10 (13.7%)
cM1-hematogenous or (pleural/peritoneal) dissemination 0 (0.0%)
Clinical stage, TNM 8th 0 0 (0.0%)
I (cT1b) 14 (19.2%)
II 8 (11.0%)
III 16 (21.9%)
IVA 25 (34.2%)
IVB (cM1-lym) 10 (13.7%)
IVB with hematogenous metastasis or (pleural/peritoneal) dissemination 0 (0.0%)
SLFN11 expression Mean ± SD, (H-score) 74.6 ± 77.7
Follow up periods Median (range) 23 (12–44)
  1. Abbreviations: SD standard deviation, eGFR estimated glomerular filtration rate, CE cervical esophagus, Ut upper thoracic esophagus, Mt middle thoracic esophagus, Lt lower thoracic esophagus, EGJ esophago-gastric junction, cT1a tumor invasion to the muscularis mucosa, cT1b tumor invasion to the submucosa, cT2 tumor invasion to the muscularis propria, cT3 tumor invasion to the adventitia, cT4a tumor invasion to the pleura, pericardium, azygos vein, diaphragm, or peritoneum, cT4b tumor invasion to other adjacent structures, such as the aorta, vertebral body, or trachea, cN0 no regional lymph node metastasis, cN1 metastasis in 1–2 regional lymph nodes, cN2 metastasis in 3–6 regional lymph nodes, cN3 metastasis in 7 or more regional lymph nodes, cM0 no distant metastasis, cM1-lym distant lymph node metastasis, CRT chemoradiotherapy, H-score histo-score
  2. All values indicate n (%) unless otherwise indicated
\